Wouter Broos

Dr. Wouter Broos

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
WBWouter Broos
Wouter Broos
MWMaurits Wondergem
Maurits Wondergem
RKRemco J. J. Knol
Remco J. J. Knol
FZFriso M. van der Zant
Friso M. van der Zant
18F-fluorocholine (FCH) PET/CT is a promising technique for visualizing hyperfunctioning parathyroid glands in hyperparathyroidism. It is still under debate whether to use this technique as a first-line imaging modality or to use it when conventional techniques such as 99mTc-sestamibi scintigraphy or ultrasonography are inconclusive. This study evaluates FCH PET/CT as a first-line modality. Patients with primary hyperparathyroidism, referred between June 2015 and December 2018 for FCH PET/CT as a first-line imaging method, were included in this study. Baseline characteristics, clinical data, scan results, and type of treatment were recorded. The rate of correct detection was calculated on a per patient-based and a per lesion-based analysis. The reference standard comprised histopathological results, intraoperative response to parathyroidectomy, and clinical follow-up. Two hundred and seventy-one patients were included, of which 139 patients underwent parathyroidectomy, 48 were treated with calcimimetics, and 84 patients received further follow-up without active treatment. In the surgically treated group, a single adenoma was suspected in 127 scans, double adenoma in three scans, and one scan showed evidence of three hyperfunctioning glands. In eight scans, no lesions were visualized. A total of 154 parathyroid glands were surgically removed. The rate of correct detection was calculated at 96% and 90%, on a per patient-based and per lesion-based analysis, respectively. This retrospective study in a large cohort shows high detection rates of FCH PET/CT in primary hyperparathyroidism, which is in accordance to literature. The use of FCH PET/CT as a first-line imaging modality in preoperative planning of parathyroid surgery may therefore be a suitable choice.

15 March 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
WBWouter Broos
Wouter Broos
MWMaurits Wondergem
Maurits Wondergem
FZFriso M. van der Zant
Friso M. van der Zant
RKRemco J.J. Knol
Remco J.J. Knol
18F-fluorocholine (FCH) PET/CT is a promising and increasingly used scan technique in preoperative imaging of parathyroid adenoma. Several acquisition methods have been evaluated in literature but the optimal image acquisition time point after administration of the tracer is still under debate. Methods: Patients with hyperparathyroidism, who received a dual-time-point FCH PET/CT (image acquisition 5 min and 60 min post injection) with histologically proven pathological parathyroid glands were retrospectively included in the study. The early versus late images were compared both visually and quantitatively. Results: Forty-six patients were included and a total of 71 parathyroid glands were surgically removed. Visually, there were no differences between early and late images of hyperfunctioning parathyroid glands in 44 patients (69%), in 13 patients (20%) visualization on early images was better, in 6 patients (9%) visualization of hyperfunctioning glands was best on late images whereas in 1 patient (2%), the lesion was exclusively visualized on late images. For the total cohort, there was a significant decrease in FCH uptake in the glands on late versus early time points (P = 0.001), but a significant increase of parathyroid-to-thyroid ratio (P = 0.037). The group of patients with better visualization on early images showed a decrease over time in both parathyroid uptake and parathyroid-to-thyroid ratio, significant in comparison to both the group with better visualization at the later time point and the group in which visualization was similar at both time points (p-values ranging 0.000-0.018). There were no significant differences in FCH uptake and parathyroid-to-thyroid ratio between the latter two groups (p-values ranging 0.200-0.709). Conclusion: In the majority of patients (89%), hyperfunctioning parathyroid glands are adequately visualized on early imaging, however in a subset of patients (11%) such glands are best visualized at a later time point. Therefore, it is recommended to acquire dual-time-point images in parathyroid imaging with FCH PET/CT, or to create an opportunity to acquire additional late images after reviewing early images when findings are inconclusive.

1 April 2018 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
WBWouter Broos
Wouter Broos
FZFriso M. van der Zant
Friso M. van der Zant
MWMaurits Wondergem
Maurits Wondergem
RKRemco J.J. Knol
Remco J.J. Knol
Objective Determination of the accuracy of sodium fluorine-18-fluoride (18F-NaF) PET/computed tomography (CT) for the evaluation of bone metastases, and the impact on patient management in breast cancer patients. Patients and methods Patients with breast cancer, referred for 18F-NaF PET/CT between February 2014 and June 2016, were included in a database. Baseline characteristics, clinical indication, definitive diagnosis according to follow-up data, as well as changes in patient management were recorded. Follow-up was performed during a period of at least 6 months using histopathologic, medical imaging, biochemical, and clinical data. Results A total of 118 patients were included in the study. Indications for 18F-NaF PET/CT included primary staging (12%), follow-up (31%), bone pain (52%), abnormal laboratory findings (5%), and evaluation of equivocal osseous lesions on other imaging modalities (3%). Bone metastases were found in 42%, whereas 53% of the scans were negative and 5% yielded equivocal results. Correlation with the reference standard yielded a sensitivity of 0.96, a specificity of 0.91, a positive predictive value of 0.89, a negative predictive value of 0.97, and an accuracy of 0.93. In 25% of the patients, the scan results led to alterations in patient management. 18F-NaF PET/CT for the evaluation of bone pain showed no explanation in 29%, benign pathology in 66%, and bone metastases in 5%. Conclusion In the present cohort of patients with breast cancer, 18F-NaF PET/CT detected bone metastases in 42% with an accuracy of 0.93. The scan results led to a change in patient management in 25%. In the evaluation of bone pain, an explanation for pain was found in 71% of the scans.

16 August 2022 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
WBWouter Broos
Wouter Broos
RKRemco J.J. Knol
Remco J.J. Knol
FZFriso M. van der Zant
Friso M. van der Zant
NSNicolaas C. Schaper
Nicolaas C. Schaper
MWMaurits Wondergem
Maurits Wondergem
Introduction 18F-choline positron emission tomography/computed tomography (PET/CT) is an upcoming imaging technique for the localization of hyperfunctioning parathyroid glands. However, 18F-choline is a nonspecific tracer that also accumulates in malignancies, inflammatory lesions, and several other benign abnormalities. The aim of this study was to determine the occurrence and relevance of incidental findings on 18F-choline PET/CT for parathyroid localization. Materials and Methods 18F-choline PET/CTs performed in our center for parathyroid localization from 2015 to 2019 were reviewed. Abnormal uptake of 18F-choline, with or without anatomical substrate on the co-registered low-dose CT and also incidental findings on CT without increased 18F-choline uptake were recorded. Each finding was correlated with follow-up data from the electronic medical records. Results A total of 388 18F-choline PET/CTs were reviewed, with 247 incidental findings detected in 226 patients (58%): 82 18F-choline positive findings with corresponding pathology on CT, 16 without CT substrate, and 149 18F-choline negative abnormalities on CT. Malignant lesions were detected in 10/388 patients (2.6%). Of all 98 detected 18F-choline positive lesions, 15 were malignant (15.3%), concerning 4 metastases and 11 primary malignancies: breast carcinoma (n = 7), lung carcinoma (n = 2), thyroid carcinoma (n = 1), and skin melanoma (n = 1). Conclusion Clinically relevant incidental findings were observed in a substantial number of patients. In 15.3% of the incidental 18F-choline positive findings, the lesions were malignant. These data contribute to better knowledge of 18F-choline distribution, enhance interpretation of 18F-choline PET/CT, and guide follow-up of incidental findings. Attention should especially be paid to breast lesions in this particular patient group with hyperparathyroidism in which women are typically over-represented. All patients gave written informed consent for the use of their anonymized data for scientific purposes. Besides the standard imaging protocol and clinical management, no additional measurements or actions affecting the patient were performed. The study was approved by the institutional research department and performed in accordance with the Declaration of Helsinki. Approval of the local ethical committee for the present study was not necessary since the study does not fall within the scope of the Dutch Medical Research Involving Human Subjects Act (section 1.b WMO, 26th February 1998). Article published online: 16 August 2022 © 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

21 May 2020 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
WBWouter Broos
Wouter Broos
MWMaurits Wondergem
Maurits Wondergem
FZFriso M. van der Zant
Friso M. van der Zant
NSNicolaas C. Schaper
Nicolaas C. Schaper
RKRemco J.J. Knol
Remco J.J. Knol
Objective: In the past few years, 18F-fluorocholine PET/CT has been established as a promising imaging technique for preoperative localization of parathyroid adenomas, but the optimal time point to start PET/CT acquisition after tracer injection is yet unknown. The aim of the present study was to assess the optimal time frame to acquire the PET/CT images and to evaluate the ability of dynamic imaging to differentiate parathyroid adenomas from active lymph nodes, a common cause for false-positive scan results. Patients and methods: Patients with primary hyperparathyroidism who had undergone a dynamic 18F-fluorocholine PET/CT positive for parathyroid disease and who subsequently underwent successful parathyroidectomy were retrospectively included in this study. On the 20 minutes dynamic images, standardized uptake value measurements were acquired per 1 minute frame for the parathyroid adenoma, the thyroid gland, blood pool activity, and, if present, lymph node activity. Results: A total of 101 patients were included in this study. Time-activity curves showed a decrease of activity in parathyroid and thyroid glands, with faster wash-out from the thyroid gland and on average a stable, lower activity in lymph nodes. Blood pool activity was particularly present in the first 2 minutes. Differentiation of a parathyroid adenoma from active lymph nodes was best before 5 minutes, but no definitive cutoff value could be determined. Differentiation of a parathyroid adenoma from the thyroid gland was best after 10 minutes. Conclusion: Dynamic imaging starting at the early time point of 2 minutes after injection of 18F-fluorocholine is useful for characterization of hyperfunctioning parathyroid glands.

1 October 2018 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
WBWouter Broos
Wouter Broos
MWMaurits Wondergem
Maurits Wondergem
FZFriso M. van der Zant
Friso M. van der Zant
RKRemco J.J. Knol
Remco J.J. Knol
A 27-year-old man, with a history of chronic renal failure due to obstructive uropathy, treated with hemodialysis and awaiting kidney transplantation, presented with tertiary hyperparathyroidism. Despite regulation of phosphate and calcium and treatment with cinacalcet, the serum parathyroid hormone levels remained elevated. The patient was referred for parathyroidectomy, and a F-18-fluorocholine PET/CT was acquired for preoperative planning. Besides visualization of the hyperfunctioning parathyroid glands, the scan also showed a typical picture of renal osteodystrophy, a finding on F-18-fluorocholine PET/CT that has not been reported before.